John David Finley - Nov 20, 2023 Form 4 Insider Report for PALISADE BIO, INC. (PALI)

Role
CEO, CFO, Director, Director
Signature
/s/ JD Finley
Stock symbol
PALI
Transactions as of
Nov 20, 2023
Transactions value $
$5,100
Form type
4
Date filed
11/24/2023, 04:00 PM
Previous filing
Nov 8, 2023
Next filing
Dec 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PALI Common Stock, par value $0.01 Award $5.1K +10K +20.93% $0.51 57.8K Nov 20, 2023 Direct F1
holding PALI Common Stock, par value $0.01 777 Nov 20, 2023 By FCW Investments, LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PALI Restricted Stock Units Award $0 +38K $0.00 38K Nov 21, 2023 Common Stock 38K Direct F3, F4, F5, F6
transaction PALI Common Stock Options Award $0 +45K $0.00 45K Nov 21, 2023 Common Stock 45K $0.59 Direct F3, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were purchased pursuant to the Palisade Bio, Inc. 2021 Employee Stock Purchase Plan, as amended ("ESPP") for the ESPP purchase period from July 1, 2023 through November 20, 2023. In accordance with the ESPP, the shares were purchased in a transaction exempt under Rule 16b-3(c) at a price equal to 85% of the closing price of the issuer's common stock on November 20, 2023.
F2 Reporting Person is the managing member of FCW Investments LLC and has the sole investment and voting power over the securities held by this entity.
F3 The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting.
F4 Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
F5 The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024.
F6 N/A.
F7 Each option represents the right to purchase one share of common stock at the exercise price.
F8 The grant vests in twelve (12) equal quarterly installments over a three (3) year period from the grant date.